PRESS-NEWS.org - Press Release Distribution
PRESS RELEASES DISTRIBUTION

Progress toward first commercial repellent for East Coast's stinker

2010-10-10
(Press-News.org) WASHINGTON, Oct. 9, 2010 — Help may be on the way for millions of people on the East Coast bugged out about the invasion of stink bugs. Scientists have reported a key advance in efforts to develop the first commercial repellent for stinkbugs, which are emerging as a major nuisance to homeowners and a devastating pest to some farm crops. They identified a natural substance in a fungus that infects a common weed and found that it shows potential as the first stinkbug repellent. Their study appeared in ACS' bi-weekly Journal of Agricultural and Food Chemistry.

Hiromitsu Nakajima and colleagues note that stinkbugs are no strangers to Japan. Indeed, they long have ranked as major pests of rice crops there and in some other countries. In contrast, the brown marmorated stinkbug seems to have gotten a foothold in the United States around 1998, and since then has spread, especially in the Mid-Atlantic states, invading homes and damaging fruit and vegetable crops. The nuisance bugs get their name from the skunk-like odor they emit when crushed or annoyed. Farmers are trying to control the pests using a variety of commercial insecticides, which kill the bugs. A stinkbug repellent could be just as effective in keeping the bugs at bay, but no reports on development of such materials have appeared in scientific journals, they say.

The scientists isolated a fungus from the green foxtail plant, a common weed found in Japan as well as the United States and other countries. The fungus lives inside the plant and appears to help protect the foxtail from insect pests and disease. In laboratory tests, extracts of the fungus strongly repelled the white-spotted stinkbug, which they used as a test subject because it is easy to collect, maintain, and handle under laboratory conditions. The scientists identified an ingredient in the extract that is capable of repelling up to 90 percent of stinkbugs and suggest that this chemical could be part of the first repellent for controlling stinkbugs. The substance repelled the stinkbugs as effectively as naphthalene, an ingredient in mothballs and a gold-standard for measuring the effects of insect repellents. A chemically modified version of the substance was almost twice as effective napthalene.

INFORMATION: ARTICLE # "3-(4-Methylfuran-3-yl)propan-1-ol: A White-Spotted Stinkbug (Eysarcoris ventralis) Repellent Produced by an Endophyte Isolated from Green Foxtail"

DOWNLOAD FULL TEXT ARTICLE http://pubs.acs.org/stoken/presspac/presspac/full/10.1021/jf904093y

CONTACT:
Hiromitsu Nakajima, Ph.D.
Department of Agricultural Chemistry
Faculty of Agriculture
Tottori University
Tottori, Japan
Phone: 81-857-31-5362
Fax: 81-857-31-5362
Email: nakajima@muses.tottori-u.ac.jp

The American Chemical Society is a non-profit organization chartered by the U.S. Congress. With more than 161,000 members, ACS is the world's largest scientific society and a global leader in providing access to chemistry-related research through its multiple databases, peer-reviewed journals and scientific conferences. Its main offices are in Washington, D.C., and Columbus, Ohio.


ELSE PRESS RELEASES FROM THIS DATE:

Clinical trials demonstrate effective weight loss strategies for obese and overweight adults

2010-10-10
CHICAGO -- Lifestyle interventions, including physical activity and structured weight loss programs, can result in significant weight loss for overweight, obese and severely obese adults, according to two reports that were posted online today by JAMA. The studies and accompanying editorials were made available early online to coincide with the presentation of these papers at the 28th Annual Scientific Meeting of the Obesity Society. The articles will appear in the October 27 print issue of JAMA. According to background information in the papers, obesity is among the ...

Prepared meals and incentivized weight-loss program for obese and overweight women

2010-10-10
In another article being released early online, Cheryl L. Rock, Ph.D., R.D., from Moores UCSD Cancer Center, La Jolla, Calif., and colleagues, conducted a randomized controlled trial of weight loss and weight maintenance in 442 overweight or obese women (BMI, 25 – 40), ages 18 to 69, over a two year period with follow-up between November 2007 and April 2010. The women were randomized into three intervention groups: in-person, center-based (167 women) or telephone based (164 women) weekly one-to-one weight loss counseling, including free-of-charge prepackaged prepared ...

New targeted therapy adds benefit to erlotinib in some patients with advanced lung cancer

2010-10-10
A subset of lung cancer patients seem to live longer and experience delays in disease progression when a new drug that targets a cancer-associated molecule called MET is added to treatment with erlotinib, the results of a double-blind Phase-II trial show. Dr David Spigel, Director of lung cancer research for the Sarah Cannon Research Institute in Nashville, Tennessee reported the trial findings at the 35th Congress of the European Society for Medical Oncology (ESMO) in Milan, Italy. The study included 128 patients with advanced non-small cell lung cancer who were ...

Surgical technique relieves painful spine fractures in patients with metastatic cancer

2010-10-10
A surgical technique appears to offer quick and effective relief for debilitating spinal fractures often suffered by patients with metastatic cancer, researchers reported at the 35th Congress of the European Society for Medical Oncology (ESMO) in Milan. Many patients with multiple myeloma, or those whose cancer has spread beyond the initial tumor site, suffer compression fractures in their spine. This is partly because the spine is one of the most common sites for metastatic spread of the disease, making the vertebrae brittle and at risk for fractures. Widely-used cancer ...

Erlotinib improves progression-free survival as first-line therapy in advanced lung cancer

2010-10-10
For patients with advanced lung cancer whose tumors carry EGFR activating mutations, first-line treatment with erlotinib nearly tripled progression-free survival compared to a standard chemotherapy combination, show results from the first prospective Phase-III study to report findings in this setting. The new results from the OPTIMAL trial were reported at the 35th Congress of the European Society for Medical Oncology (ESMO) in Milan, Italy. "Erlotinib is very effective and well tolerated in advanced NSCLC patients who harbor EGFR activating mutations. It is 2 to 3 ...

Identifying subsets of patients who will respond to subsequent lines of chemotherapy

2010-10-10
In a study presented at the 35th Congress of the European Society for Medical Oncology (ESMO), Dr Giovanni Bernardo from Fondazione Maugeri in Pavia, Italy, presented results that suggested it may be possible to identify subsets of metastatic breast cancer patients who are likely to respond to subsequent lines of chemotherapy. Dr Bernardo's group analysed data from 980 women treated with chemotherapy for metastatic breast cancer in their centre between 1992 and 2006. They found that the median overall survival grew progressively smaller for each successive chemotherapy ...

Study reveals cancer-linked epigenetic effects of smoking

2010-10-10
For the first time, UK scientists have reported direct evidence that taking up smoking results in epigenetic changes associated with the development of cancer. The results were reported at the 35th Congress of the European Society for Medical Oncology (ESMO) in Milan, Italy. The link between smoking and cancer has been established for decades, explained Dr Yuk Ting Ma from the Cancer Research UK Institute of Cancer Studies, Birmingham, who presented the results. Smoking is the single biggest cause of cancer in the world, and years of research have confirmed that carcinogenic ...

Investigational ovarian cancer drug shows promise against platinum resistant disease

2010-10-10
A drug being developed as a treatment for ovarian cancer has shown single agent activity with durable disease control in some patients in a Phase-II clinical trial, an international research group has reported. Dr Ursula Matulonis from Dana-Farber Cancer Institute in the USA reported the results of the single-agent trial of the drug, called MLN8237, in a poster at the 35th Congress of the European Society for Medical Oncology (ESMO). MLN8237 selectively inhibits an enzyme known as Aurora A kinase, which is a member of a family of kinase enzymes involved in normal ...

Ameripro Appliance Repair Los Angeles

2010-10-10
Ameripro Appliance Repair is the leading home, business and commercial appliance repair company in Los Angeles. Air conditioning is a wonderful thing for some people to use when the summer heat strikes. However, some people may not think about getting some of the regular maintenance carried out of the machine. Then when they go to use the machine they discover that it does not function. That is when they will want to know about the positives of Los Angeles air conditioning repair information and how it can help a person in determining the issue and knowing which service ...

MyVideoTalk Has Hit the Ground Running in the New York Area With SupremeTeam

2010-10-10
MyVideoTalk was founded in 2004 and is a division of Team Effort International, LLC, a privately held, debt-free company founded in 2002 with global offices in Northern California, USA. Their mission is "Bring the World Closer Together" by utilizing cutting-edge Internet communication technologies and bringing them to the global marketplace. Their products are state-of-the-art, user-friendly, and continually enhanced for better and more functionality. The products are simple enough for anyone to use and sophisticated enough for businesses to greatly improve their marketing ...

LAST 30 PRESS RELEASES:

Loss of key visual channel triggers rhythmic retinal signals linked to night blindness

New study suggests chiral skyrmion flows can be used for logic devices

AASM congratulates Sleep Medicine Disruptors Innovation Award winners

The future fate of water in the Andes

UC Irvine researchers link Antarctic ice loss to ‘storms’ at the ocean’s subsurface

Deep brain stimulation successful for one in two patients with treatment-resistant severe depression and anxiety

Single-celled organisms found to have a more complex DNA epigenetic code than multicellular life

A new gateway to global antimicrobial resistance data

Weather behind past heat waves could return far deadlier

Ultrasonic device dramatically speeds harvesting of water from the air

Artificial intelligence can improve psychiatric diagnosis

Watch cells trek along vesicle ‘breadcrumbs’

University of Liverpool unveils plans to establish UK’s flagship AI-driven materials discovery centre

ARC at Sheba Medical Center and Mount Sinai launch collaboration with NVIDIA to crack the hidden code of the human genome through AI

SRL welcomes first Deputy Editor-in-Chief

Time to act and not react: how can the European Union turn the tide of antimicrobial resistance?

Apriori Bio and A*STAR Infectious Diseases Labs Announce strategic partnership to advance next generation influenza vaccines

AI and extended reality help to preserve built cultural heritage

A new way to trigger responses in the body

Teeth of babies of stressed mothers come out earlier, suggests study

Slimming with seeds: Cumin curry spice fights fat

Leak-proof gasket with functionalized boron nitride nanoflakes enhances performance and durability

Gallup and West Health unveil new state rankings of Americans’ healthcare experiences

Predicting disease outbreaks using social media 

Linearizing tactile sensing: A soft 3D lattice sensor for accurate human-machine interactions

Nearly half of Australian adults experienced childhood trauma, increasing mental illness risk by 50 percent

HKUMed finds depression doubles mortality rates and increases suicide risk 10-fold; timely treatment can reduce risk by up to 30%

HKU researchers develop innovative vascularized tumor model to advance cancer immunotherapy

Floating solar panels show promise, but environmental impacts vary by location, study finds

Molecule that could cause COVID clotting key to new treatments

[Press-News.org] Progress toward first commercial repellent for East Coast's stinker